|
1
|
Gerratana L, Basile D, Buono G, De Placido S, Giuliano M, Minichillo S, Coinu A, Martorana F, De Santo I, Del Mastro L, et al: Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. Cancer Treat Rev. 68:102–110. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vagia E, Mahalingam D and Cristofanilli M: The landscape of targeted therapies in TNBC. Cancers (Basel). 12:9162020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 121:2750–2767. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, Xiao Y, Yu KD, Liu YR, Yu Y, et al: Genomic and transcriptomic landscape of triple-negative breast cancers: Subtypes and treatment strategies. Cancer Cell. 35:428–440.e5. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kono M, Fujii T, Lim B, Karuturi MS, Tripathy D and Ueno NT: Androgen receptor function and androgen receptor-targeted therapies in breast cancer: A review. JAMA Oncol. 3:1266–1273. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ, et al: The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 7:114792016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Narayanan R and Dalton JT: Androgen receptor: A complex therapeutic target for breast cancer. Cancers (Basel). 8:1082016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, et al: Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 371:424–433. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 367:1187–1197. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Caiazza F, Murray A, Madden SF, Synnott NC, Ryan EJ, O'Donovan N, Crown J and Duffy MJ: Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells. Endocr Relat Cancer. 23:323–334. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, et al: Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol. 36:884–890. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jiang YZ, Liu Y, Xiao Y, Hu X, Jiang L, Zuo WJ, Ma D, Ding J, Zhu X, Zou J, et al: Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: The FUTURE trial. Cell Res. 31:178–186. 2021. View Article : Google Scholar :
|
|
14
|
Soldi R, Cohen AL, Cheng L, Sun Y, Moos PJ and Bild AH: A genomic approach to predict synergistic combinations for breast cancer treatment. Pharmacogenomics J. 13:94–104. 2013. View Article : Google Scholar
|
|
15
|
Bates SE: Epigenetic therapies for cancer. N Engl J Med. 383:650–663. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fedele P, Orlando L and Cinieri S: Targeting triple negative breast cancer with histone deacetylase inhibitors. Expert Opin Investig Drugs. 26:1199–1206. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ning ZQ, Li ZB, Newman MJ, Shan S, Wang XH, Pan DS, Zhang J, Dong M, Du X and Lu XP: Chidamide (CS055/HBI-8000): A new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 69:901–909. 2012. View Article : Google Scholar
|
|
18
|
Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, Yu L, Ke X, Huang H, Shen Z, et al: Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 26:1766–1771. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shi Y, Jia B, Xu W, Li W, Liu T, Liu P, Zhao W, Zhang H, Sun X, Yang H, et al: Chidamide in relapsed or refractory peripheral T cell lymphoma: A multicenter real-world study in China. J Hematol Oncol. 10:692017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jiang Z, Li W, Hu X, Zhang Q, Sun T, Cui S, Wang S, Ouyang Q, Yin Y, Geng C, et al: Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20:806–815. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tu K, Yu Y, Wang Y, Yang T, Hu Q, Qin X, Tu J, Yang C, Kong L and Zhang Z: Combination of chidamide-mediated epigenetic modulation with immunotherapy: Boosting tumor immunogenicity and response to PD-1/PD-L1 blockade. ACS Appl Mater Interfaces. 13:39003–39017. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
National Institutes of Health: Guide for the care and use of laboratory animals. 7th edition. National Academy Press; Washington DC: 1996
|
|
23
|
Guidelines for Euthanasia of Rodents Using Carbon Dioxide. 2020 Edition. https://oacu.oir.nih.gov/system/files/media/file/2021-06/b5_euthanasia_of_rodents_using_carbon_dioxide.pdf.
|
|
24
|
Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L, et al: clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2:1001412021.PubMed/NCBI
|
|
25
|
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
27
|
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, et al: Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 381:121–131. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP, et al: Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 382:2197–2206. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu YW, Xia R, Lu K, Xie M, Yang F, Sun M, De W, Wang C and Ji G: LincRNAFEZF1-AS1 represses p21 expression to promote gastric cancer proliferation through LSD1-Mediated H3K4me2 demethylation. Mol Cancer. 16:392017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ma X, Wang L, Huang D, Li Y, Yang D, Li T, Li F, Sun L, Wei H, He K, et al: Polo-like kinase 1 coordinates biosynthesis during cell cycle progression by directly activating pentose phosphate pathway. Nat Commun. 8:15062017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pack LR, Daigh LH and Meyer T: Putting the brakes on the cell cycle: Mechanisms of cellular growth arrest. Curr Opin Cell Biol. 60:106–113. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sherr CJ, Beach D and Shapiro GI: Targeting CDK4 and CDK6: From discovery to therapy. Cancer Discov. 6:353–367. 2016. View Article : Google Scholar :
|
|
33
|
Webb CP, Van Aelst L, Wigler MH and Vande Woude GF: Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc Natl Acad Sci USA. 95:8773–8778. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Marte BM, Rodriguez-Viciana P, Wennström S, Warne PH and Downward J: R-Ras can activate the phosphoinositide 3-kinase but not the MAP kinase arm of the Ras effector pathways. Curr Biol. 7:63–70. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Metz HE, Kargl J, Busch SE, Kim KH, Kurland BF, Abberbock SR, Randolph-Habecker J, Knoblaugh SE, Kolls JK, White MF and Houghton AM: Insulin receptor substrate-1 deficiency drives a proinflammatory phenotype in KRAS mutant lung adenocarcinoma. Proc Natl Acad Sci USA. 113:8795–8800. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, Stolz DB, Land SR, Marconcini LA, Kliment CR, et al: Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med. 16:219–223. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hu R, Dawood S, Holmes MD, Collins LC, Schnitt SJ, Cole K, Marotti JD, Hankinson SE, Colditz GA and Tamimi RM: Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res. 17:1867–1874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, et al: Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res. 19:5505–5512. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Traina TA, Miller K, Yardley DA, O'Shaughnessy J, Cortes J, Awada A, Kelly CM, Trudeau ME, Schmid P, Gianni L, et al: Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). J Clin Oncol. 33(Suppl 15): S10032015. View Article : Google Scholar
|
|
40
|
Gucalp A, Proverbs-Singh TA, Corben A, Moynahan ME, Patil S, Boyle LA, Hudis CA and Traina TA: Phase I/II trial of palbociclib in combination with bicalutamide for the treatment of androgen receptor (AR)+ metastatic breast cancer (MBC). J Clin Oncol. 34(15 Suppl): TPS11032016. View Article : Google Scholar
|
|
41
|
Robles AJ, Cai S, Cichewicz RH and Mooberry SL: Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer. Breast Cancer Res Treat. 157:475–488. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hu WY, Xu L, Chen B, Ou S, Muzzarelli KM, Hu DP, Li Y, Yang Z, Vander Griend DJ, Prins GS and Qin Z: Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75. Prostate. 79:1166–1179. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Que Y, Zhang XL, Liu ZX, Zhao JJ, Pan QZ, Wen XZ, Xiao W, Xu BS, Hong DC, Guo TH, et al: Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma. J Immunother Cancer. 9:e0016962021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ding S, Gao Y, Lv D, Tao Y, Liu S, Chen C, Huang Z, Zheng S, Hu Y, Chow LKY, et al: DNTTIP1 promotes nasopharyngeal carcinoma metastasis via recruiting HDAC1 to DUSP2 promoter and activating ERK signaling pathway. EBioMedicine. 81:1041002022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Saltiel AR and Kahn CR: Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 414:799–806. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mardilovich K, Pankratz SL and Shaw LM: Expression and function of the insulin receptor substrate proteins in cancer. Cell Commun Signal. 7:142009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Porter HA, Perry A, Kingsley C, Tran NL and Keegan AD: IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors. Cancer Lett. 338:239–248. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Topacio BR, Zatulovskiy E, Cristea S, Xie S, Tambo CS, Rubin SM, Sage J, Kõivomägi M and Skotheim JM: Cyclin D-Cdk4,6 drives cell-cycle progression via the retinoblastoma protein's C-terminal helix. Mol Cell. 74:758–770.e4. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M and Kristiansen DG: Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 98:604–610. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ramaiah MJ, Tangutur AD and Manyam RR: Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. Life Sci. 277:1195042021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wei H, Ma W, Lu X, Liu H, Lin K, Wang Y, Ye Z, Sun L, Huang Z, Pan T, et al: KDELR2 promotes breast cancer proliferation via HDAC3-mediated cell cycle progression. Cancer Commun (Lond). 41:904–920. 2021. View Article : Google Scholar : PubMed/NCBI
|
